Immunic (NASDAQ:IMUX) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report released on Monday morning.

Several other equities analysts have also recently weighed in on the company. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research note on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. B. Riley assumed coverage on shares of Immunic in a research note on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective for the company. Leerink Partners restated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price target on shares of Immunic in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.25.

Immunic Stock Performance

IMUX stock opened at $1.09 on Monday. Immunic has a twelve month low of $0.97 and a twelve month high of $2.11. The stock’s 50 day moving average is $1.45 and its 200-day moving average is $1.35.

Insider Activity

In other Immunic news, Director Richard Alan Rudick acquired 87,300 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now owns 87,300 shares in the company, valued at $100,395. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Immunic

A number of hedge funds have recently modified their holdings of IMUX. Virtu Financial LLC purchased a new position in Immunic in the 1st quarter worth about $25,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. Ikarian Capital LLC grew its holdings in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Vanguard Group Inc. lifted its position in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Immunic in the first quarter worth $9,266,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.